CEACAM5 and lung cancer: For instance, CAR-T cells directed against CEA and MUC1, two TSA that are highly expressed in lung cancer, are being evaluated for safety and efficacy in the NCT02349724 (264), NCT04348643 (265), NCT03525782 (266), NCT02587689 (267), NCT05239143 (268) clinical trials (9, 269, 270).